Real-world genomic analysis highlights unmet medical need in GU cancer patients with TSC1/2 inactivating alterations LOS ANGELES, Jan. 26, 2024 /PRNewswire/ — Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.